Literature DB >> 477708

Intracardiac electrophysiological effects of lorcainide in man.

C K Ng, M Gstöttner, R Gmeiner.   

Abstract

The electrophysiological effects of lorcainide 1.25 or 2.5 mg/kg given iv over 2 or 4 min, were studied in 21 patients with normal and diseased impulse formation and conduction, by means of intracardiac recording and stimulation. Sinus rate and the effective atrial refractory period rose following both doses of lorcainide. The corrected sinus node recovery time rose only after lorcainide 2.5 mg/kg and then most markedly in patients with sinus node dysfunction. The P-A interval remained unchanged following the drug. The A-H interval during sinus rhythm, and the pooled A-H intervals during atrial pacing, increased slightly, and the functional and effective A-V nodal refactory period changed variably. Wenckebach periods above the bundle of His occurred at lower atrial pacing rates following both doses of lorcainide in 7 patients, at the same atrial pacing rate in 9 and at higher rates in 3. H-V intervals, pooled H-V intervals and QRS-width lengthened in all patients, most markedly in cases with a conduction delay below the His bundle, who had received lorcainide 2.5 mg/kg. Thus, lorcainide shares some electrophysiological properties with procainamide and aprindine. Higher doses should be used with caution in patients with pre-existing conduction delay below the bundle His.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 477708     DOI: 10.1007/bf00618512

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  13 in total

1.  Action of antiarrhythmic drugs on His bundle electrogram and sinus node function.

Authors:  L Seipel; A Both; G Breithardt; U Gleichmann; F Loogen
Journal:  Acta Cardiol       Date:  1974       Impact factor: 1.718

2.  Significance of the sinus-node recovery time.

Authors:  O S Narula; P Samet; R P Javier
Journal:  Circulation       Date:  1972-01       Impact factor: 29.690

3.  Electrophysiologic properties of procainamide in man.

Authors:  M E Josephson; A R Caracta; M A Ricciutti; S H Lau; A N Damato
Journal:  Am J Cardiol       Date:  1974-05-06       Impact factor: 2.778

4.  Atrioventricular block with lidocaine therapy.

Authors:  E Lichstein; K D Chadda; P K Gupta
Journal:  Am J Cardiol       Date:  1973-02       Impact factor: 2.778

5.  Pervenous pacing of the specialized conducting system in man. His bundle and A-V nodal stimulation.

Authors:  O S Narula; B J Scherlag; P Samet
Journal:  Circulation       Date:  1970-01       Impact factor: 29.690

6.  Catheter technique for recording His bundle activity in man.

Authors:  B J Scherlag; S H Lau; R H Helfant; W D Berkowitz; E Stein; A N Damato
Journal:  Circulation       Date:  1969-01       Impact factor: 29.690

7.  Evaluation of sino-atrial node function in man by overdrive suppression.

Authors:  W Mandel; H Hayakawa; R Danzig; H S Marcus
Journal:  Circulation       Date:  1971-07       Impact factor: 29.690

8.  Electrophysiologic effects of procainamide in subtherapeutic to therapeutic doses on human atrioventricular conduction system.

Authors:  J B Ogunkelu; A N Damato; M Akhtar; C P Reddy; A R Caracta; S H Lau
Journal:  Am J Cardiol       Date:  1976-04       Impact factor: 2.778

9.  Electrophysiological effects of mexiletine in man.

Authors:  J C Roos; A C Paalman; A J Dunning
Journal:  Br Heart J       Date:  1976-12

10.  Antiarrhythmic, electrophysiologic and hemodynamic effects of lorcainide.

Authors:  E Carmeliet; P A Janssen; R Marsboom; J M Van Nueten; R Xhonneux
Journal:  Arch Int Pharmacodyn Ther       Date:  1978-01
View more
  2 in total

1.  Electrophysiological effects of lorcainide, a new antiarrhythmic drug. Observations in patients with and without pre-excitation.

Authors:  F W Bär; J Farré; D Ross; E J Vanagt; A P Gorgels; H J Wellens
Journal:  Br Heart J       Date:  1981-03

Review 2.  Lorcainide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy.

Authors:  C e Eiriksson; R N Brogden
Journal:  Drugs       Date:  1984-04       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.